SAM
REGN icon

Silvercrest Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Silvercrest Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,079
Closed -$521K – 868
2020
Q4 		$521K Buy
1,079
+25
+2% +$13.5K ﹤0.01% 625
2020
Q3 		$590K Buy
1,054
+4
+0.4% +$2.42K 0.01% 582
2020
Q2 		$655K Hold
1,050
– – 0.01% 569
2020
Q1 		$513K Buy
+1,050
New +$433K 0.01% 567

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Silvercrest Asset Management's REGN Position: Q1 2021 in Review

Silvercrest Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2021, closing a stake of 1,079 shares — an estimated $521K sold.

Silvercrest Asset Management first reported a position in REGN in Q1 2020 and held it in 4 quarters. The position peaked at $655K in Q2 2020. 924 funds tracked by Wall St. Rank hold REGN as of Q1 2021.

  • Silvercrest Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Silvercrest Asset Management sold 1,079 Regeneron Pharmaceuticals shares in Q1 2021, an estimated $521K.
  • Silvercrest Asset Management first reported a position in Regeneron Pharmaceuticals in Q1 2020 and held it in 4 quarters.
  • Silvercrest Asset Management's Regeneron Pharmaceuticals position peaked at $655K in Q2 2020.
  • 924 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2021.

Based on Silvercrest Asset Management's 13F filing for Q1 2021, filed 17 May 2021.